RxDoctor Payments Data

Mousa Alwawi, MD

Internal Medicine · Warner Robins, GANPI 1922057876

Payments from drug & device makers

$10,245in general payments, 2019–2025

Across 538 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Abbott$958
  • AstraZeneca$752
  • Bayer$723
  • Amgen$653
  • AbbVie$637
  • plus $5K from 52 others

What the payments were for

  • Travel & lodging$4855%
  • Food & beverage$9,67394%
  • Education$871%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk85$1,270
Abbott8$958
AstraZeneca48$752
Bayer35$723
Amgen(2 entities)38$653
AbbVie(2 entities)35$637
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC31$529
Otsuka America Pharmaceutical, Inc.25$511
Astellas Pharma US Inc20$470
Lilly USA, LLC23$387
GSK19$282
Neos Therapeutics, LP15$258
Novartis12$235
Boehringer Ingelheim9$218
Johnson & Johnson9$214
Mylan Specialty L.p.12$212
Axsome Therapeutics, Inc.9$179
Pfizer7$138
Phathom Pharmaceuticals, Inc.8$136
Upsher-smith Laboratories LLC8$126
Sanofi-aventis U.S. LLC6$100
Lundbeck LLC5$97
Eisai Inc.5$93
Supernus Pharmaceuticals, Inc.5$77
Kowa Pharmaceuticals America, Inc.5$72
Teva Pharmaceuticals USA, Inc.5$71
Antares Pharma, Inc.3$63
Biohaven Pharmaceuticals, Inc.4$59
Aytu Biopharma, Inc.4$51
Biogen2$48
Sumitomo Pharma America, Inc.2$43
Xeris Pharmaceuticals, Inc.2$41
Arbor Pharmaceuticals, Inc.3$38
Daiichi Sankyo Inc.2$36
Biohaven Pharmaceutical Holding Company Ltd.2$32
E.r. Squibb & Sons, L.L.C.2$29
Jazz Pharmaceuticals Inc.2$28
Adlon Therapeutics L.p.2$28
Baxter Healthcare1$27
Viatris Specialty LLC1$26
Intra-sana Laboratories2$25
Abiomed1$24
Shield Therapeutics Inc1$20
Takeda Pharmaceuticals U.S.A., Inc.1$20
Noven Therapeutics, LLC1$19
Almatica Pharma LLC1$18
Exact Sciences1$17
Smith+Nephew1$17
Clarus Therapeutics Inc.1$17
Amarin Pharma, Inc.1$17
Esperion Therapeutics, Inc.1$16
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$16
Dexcom, Inc.1$13
Senseonics, Incorporated1$13
Tolmar, Inc.1$13
Nevro Corp.1$12
Global Blood Therapeutics, Inc.1$12
Shionogi Inc1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,245 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$192,295
Medicare patients
675
Services billed
2,697

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide179$194,560
MounjaroTirzepatide149$171,825
EliquisApixaban123$109,325
JardianceEmpagliflozin85$88,554
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$43,539
JanuviaSitagliptin Phosphate35$39,795
TrulicityDulaglutide32$38,920
MyrbetriqMirabegron36$29,310
XareltoRivaroxaban37$28,871
Tresiba Flextouch U-200Insulin Degludec29$28,369
Breztri AerosphereBudesonide/Glycopyr/Formoterol34$27,633
EntrestoSacubitril/Valsartan32$27,522
RybelsusSemaglutide24$26,042
LinzessLinaclotide36$24,847
FarxigaDapagliflozin Propanediol20$12,972

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,270$220,602203 claims
Lilly USA, LLCMounjaro, Trulicity$387$210,745181 claims
PfizerEliquis$138$109,325123 claims
Boehringer IngelheimJardiance, Stiolto Respimat$218$93,90996 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$752$44,54765 claims
GSKTrelegy Ellipta$282$43,53945 claims
Astellas Pharma US IncMyrbetriq$470$29,31036 claims
Johnson & JohnsonXarelto$214$28,87137 claims
NovartisEntresto$235$27,52232 claims
AbbVieLinzess$637$24,84736 claims
BayerKerendia$723$6,96511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Warner Robins

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →